A Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis

Seborrheic dermatitis (SD) is a chronic inflammatory skin condition driven by overactive sebaceous glands, Malassezia colonization, immune dysfunction, and epidermal barrier disruption. While topical corticosteroids and antifungals are first-line treatments, rebound disease and adverse effects limit long-term use.

To evaluate seven off-label therapies for SD: topical calcineurin inhibitors (TCI), metronidazole, phosphodiesterase-4 inhibitors (PDE4), systemic antifungals, isotretinoin, natural remedies, and microbiome-directed therapies.

A PubMed-based narrative review included clinical trials, observational studies, and case reports when higher-level data were lacking.

TCIs and PDE4 inhibitors demonstrated consistent efficacy for facial SD as steroid-sparing options. Metronidazole provided modest benefit, mainly in patients with concomitant rosacea. Both systemic antifungals and low-dose isotretinoin were effective for moderate-to-severe disease, though systemic therapy requires monitoring for hepatotoxicity. Natural agents (eg, honey, tea tree oil) and microbiome-targeted therapies (eg, probiotics, Triphala) showed variable improvement.

These therapies serve as promising treatment options for SD, particularly in refractory cases or when standard treatments are unsuitable. Larger comparative trials with standardized outcomes and long-term follow-up are needed to clarify their role.